Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sarepta Therapeutics

62.40
+1.552.55%
Post-market: 62.400.00000.00%16:05 EDT
Volume:1.77M
Turnover:109.34M
Market Cap:6.05B
PE:26.69
High:62.51
Open:59.98
Low:59.62
Close:60.85
Loading ...

Arrowhead to receives $500M upfront in licensing pact with Sarepta

TIPRANKS
·
10 Feb

Nvidia And 2 Other High Growth Tech Stocks In The United States

Simply Wall St.
·
06 Feb

The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex

Zacks
·
06 Feb

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Delivered A Weaker ROE Than Its Industry

Simply Wall St.
·
05 Feb

Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?

Zacks
·
03 Feb

Jim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’

Insider Monkey
·
31 Jan

Sarepta Therapeutics Price Target Maintained With a $75.00/Share by HC Wainwright & Co.

Dow Jones
·
30 Jan

Sarepta told RBC patient death confirmed unrelated to Elevidys

TIPRANKS
·
29 Jan

Sarepta could be down on patient death in FDA database, says RBC Capital

TIPRANKS
·
29 Jan

TD Cowen Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
28 Jan

Sarepta Therapeutics: Buy Rating Affirmed on Positive EMBARK Study Results and Strong Financial Outlook

TIPRANKS
·
28 Jan

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT) and Roche Holding AG (OtherRHHVF)

TIPRANKS
·
28 Jan

Sarepta Therapeutics Price Target Maintained With a $202.00/Share by Needham

Dow Jones
·
28 Jan

Mizuho Securities Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
28 Jan

Buy Rating Reaffirmed for Sarepta Therapeutics Following Positive EMBARK Study Results

TIPRANKS
·
28 Jan

Sarepta announces topline results from EMBARK study

TIPRANKS
·
27 Jan

Sarepta Therapeutics Says Phase 3 Study of Potential Muscular Dystrophy Drug Shows 'Positive' Results

MT Newswires Live
·
27 Jan

Sarepta Therapeutics Announces Results From Part 2 of the Embark Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals With Duchenne Muscular Dystrophy Following Treatment With Elevidys

THOMSON REUTERS
·
27 Jan

RBC Capital Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
23 Jan

TD Cowen Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
21 Jan